These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 26359571

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C, Garcia-Velloso MJ, Lozano MD, Labiano T, Vigil Diaz C, Lopez-Picazo JM, Gurpide A, Zulueta JJ, Richter Echevarria JA, Perez Gracia JL.
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.
    Na II, Byun BH, Kim KM, Cheon GJ, Choe du H, Koh JS, Lee DY, Ryoo BY, Baek H, Lim SM, Yang SH, Kim CH, Lee JC.
    Lung Cancer; 2010 Jan; 67(1):76-80. PubMed ID: 19371962
    [Abstract] [Full Text] [Related]

  • 5. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
    Yoshida T, Tanaka H, Kuroda H, Shimizu J, Horio Y, Sakao Y, Inaba Y, Iwata H, Hida T, Yatabe Y.
    Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
    [Abstract] [Full Text] [Related]

  • 6. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
    Liu A, Han A, Zhu H, Ma L, Huang Y, Li M, Jin F, Yang Q, Yu J.
    Oncotarget; 2017 May 16; 8(20):33736-33744. PubMed ID: 28422710
    [Abstract] [Full Text] [Related]

  • 7. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
    Shiri I, Maleki H, Hajianfar G, Abdollahi H, Ashrafinia S, Hatt M, Zaidi H, Oveisi M, Rahmim A.
    Mol Imaging Biol; 2020 Aug 16; 22(4):1132-1148. PubMed ID: 32185618
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.
    J Thorac Oncol; 2009 Jan 16; 4(1):12-21. PubMed ID: 19096301
    [Abstract] [Full Text] [Related]

  • 13. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J, Kobayashi Y, Urayama KY, Yamaura H, Yatabe Y, Hida T.
    PLoS One; 2016 Jan 16; 11(8):e0161081. PubMed ID: 27518729
    [Abstract] [Full Text] [Related]

  • 14. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
    Han JY, Choi JJ, Kim JY, Han YL, Lee GK.
    BMC Cancer; 2016 Aug 12; 16():627. PubMed ID: 27519791
    [Abstract] [Full Text] [Related]

  • 15. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.
    J Thorac Oncol; 2011 Apr 12; 6(4):707-15. PubMed ID: 21258250
    [Abstract] [Full Text] [Related]

  • 16. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
    Cho A, Hur J, Moon YW, Hong SR, Suh YJ, Kim YJ, Im DJ, Hong YJ, Lee HJ, Kim YJ, Shim HS, Lee JS, Kim JH, Choi BW.
    BMC Cancer; 2016 Mar 16; 16():224. PubMed ID: 26979333
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y, Onishi H, Nambu A, Araki T.
    Radiology; 2014 Jan 16; 270(1):275-81. PubMed ID: 24029640
    [Abstract] [Full Text] [Related]

  • 19. Correlation between EGFR mutation status and F18 -fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma.
    Zhu L, Yin G, Chen W, Li X, Yu X, Zhu X, Jiang W, Jia C, Chen P, Zhang Y, Lu D, Yu L, Li X, Xu W.
    Thorac Cancer; 2019 Apr 16; 10(4):659-664. PubMed ID: 30776196
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.